Phar­ma rep­u­ta­tion re­tains 'halo' even as pan­dem­ic me­dia cov­er­age re­cedes — sur­vey

The Covid-19 ha­lo ef­fect on the phar­ma in­dus­try is con­tin­u­ing, ac­cord­ing to a new glob­al study from Ip­sos. The an­nu­al sur­vey for the In­ter­na­tion­al Fed­er­a­tion of Phar­ma­ceu­ti­cal Man­u­fac­tur­ers and As­so­ci­a­tions (IF­P­MA) finds con­sid­er­able good­will from con­sumers across mea­sures of trust, co­op­er­a­tion with gov­ern­ments, and ad­vanc­ing re­search and drug de­vel­op­ment.

“De­spite the pan­dem­ic in many coun­tries no longer be­ing the top of mind con­cern gen­er­al­ly – al­though it does re­main the top con­cern as a health is­sue – the in­dus­try’s rep­u­ta­tion has re­mained pos­i­tive,” said Ip­sos re­search di­rec­tor Thomas Fife-Schaw.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER